Saturday, November 22, 2008

Schizophrenia Home>
News>
Study: Abilify has lower diabetes, heart disease risk

Study: Abilify has lower diabetes, heart disease risk

(HealthCentral.com) UPDATED 2008-06-14

Patients who suffer from schizophrenia who are treated with Abilify have more favorable changes in blood sugar, lipids, and body weight, compared to those who take older antipsychotic drugs, researchers say. Schizophrenics have a higher risk of developing diabetes and heart disease because of metabolic changes related to the use of medications to control their condition. But investigators say the findings about Abilify may translate into lower risk for diabetes and heart disease in patients who use the drug. Read full story >

See all Schizophrenia News

Related: Abilify

Bookmark

Was this helpful? Yes

Save to My Home
Want to keep this page handy for later? Click Save to My Home and we'll add it to your My Home area.

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Non-Profit Affiliates:

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on SchizophreniaConnection.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2008. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.